Abstract
In 1998, the Tunisian team of the ‘Centre National de Greffe de Moelle Osseuse’ initiated allogeneic hematopoietic SCT (AHSCT) in Tunisia. As of June 2007, information was collected about 299 patients with a first AHSCT and 12 additional retransplants. The median age was 19 years (range 2–49 years). The main indications were aplastic anemia (n=106, 36%), leukemia and nonmalignant disorders (n=153, 51%), Fanconi anemia (n=26, 9%) and other nonmalignant disorders (n=14, 4%). Preparative regimens depended on indication. All donors were HLA geno-identical. The stem cell sources were BM (87%) and PBSCs (13%). At the time of analysis, 200 patients (67%) were alive after a median follow-up of 42 months (range 3–112 months). The overall TRM rate was 17%. Outcome depended on indication. According to our results, allogeneic HSCT is potentially curative for hematological diseases, but it is a toxic approach for malignant disorders.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Thomas ED . Bone marrow transplantation: a review. Semin Hematol 1999; 36: 95–103.
Horowitz M . Uses and growth of hematopoietic cell transplantation. In: Blume KG, Forman SJ, Appelbaum FR (eds). Thomas' Hematopoietic Cell Transplantation. Blackwell Scientific Publishers Inc.: London, New York, 2004, pp 9–15.
Gratwoh A, Baldoremo H, Frauendorfer K, Urbano-Ispizua A, Niederwieser D, for the Joint Accreditation Committee of the International Society for Cellular Therapy ISCT and The European Group for Blood and Marrow Transplantation EBMT (JACIE). Results of the EBMT activity survey 2005 on haematopoietic stem ell transplantation; focus on increasing use of unrelated donors. Bone Marrow Transplant 2007; 39: 71–87.
Schmitz N, Gratwohl A, Golman JM . Allogeneic and autologous transplantation for haematologic diseases, solid tumours and immune disorders: current practice in Europe in 1996 and proposals for an operational classification. Bone Marrow transplant 1996; 17: 471–477.
Torjemane L, Ladeb S, Ben Othman T, Abdelkefi A, Lakhal A, Ben Abdeladhim A . Bone marrow transplantation from matched related donors for patients with Fanconi anaemia using low-dose busulfan and cyclophosphamide as conditioning. Pediatr Blood Cancer 2006; 46: 496–500.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ben Othman, T., Torjemane, L., Abdelkefi, A. et al. Allogeneic hematopoietic stem cell transplantation in Tunisia. Bone Marrow Transplant 42 (Suppl 1), S139–S141 (2008). https://doi.org/10.1038/bmt.2008.143
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2008.143
Keywords
This article is cited by
-
A practical approach for adoption of a hub and spoke model for cell and gene therapies in low- and middle-income countries: framework and case studies
Gene Therapy (2024)
-
Special issues related to hematopoietic SCT in the Eastern Mediterranean region and the first regional activity report
Bone Marrow Transplantation (2009)